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The hypothesis that neurosteroids are synthesized and active in the nervous system is
well-established among neuroscientists. Their presence was shown for the first time more than
20 years ago (Baulieu and Robel, 1990), however we believe that different neurosteroids actions
in central (brain and spinal cord) and peripheral nervous system are not still fully elucidated,
deserving further investigation.
Allopregnanolone (Allo) is the most important neurosteroid (Baulieu and Robel, 1990),
targeting both neurons and glial cells in central and periphery, primarily through rapid
“non-genomic” action via γ-amino butyric acid (GABA) type A receptor (GABA-AR). Given
these prerogatives, Allo is a promising drug for development of novel neuroprotective and
neuroregenerative strategies, as well as for the treatment of neuropsychiatric disorders. Rupprecht
overviewed the state of the art of Allo’s actions in the brain, suggesting different molecular
mechanisms beyond the GABA-AR interaction. He explores the therapeutic use of Allo and its
synthetic analogous ganaxolone in human psychiatric disorders, suggesting that the analysis of
neurosteroid profile in neuropsychiatric patients is necessary (Rupprecht, 2014). Ganaxolone has
been recently proposed for epilepsy and infantile spasms treatments (Riikonen, 2014), however
its use for neuropsychiatric diseases is emerging. The posttraumatic stress disorder (PTSD) is a
severe neuropsychiatric condition for which efficient therapies are still lacking. Ganaxolone, acting
on GABAergic system, is a therapeutic alternative to the serotonin reuptake inhibitors, the only
drugs currently approved by the Food and Drug Administration for PTSD. Pinna and Rasmusson
suggested that restoring Allo’s brain levels is beneficial in PTSD patients. Using an in vivo PSTD
mice model, they also demonstrated that the increased corticolimbic levels of Allo reduce the
PTSD-like behavior. Therefore, they proposed ganaxolone as alternative treatment for patients
suffering PTSD or other disorders implying Allo biosynthesis impairment (Pinna and Rasmusson,
2014).
Allo has recently emerged as neurogenic molecule acting on neural progenitor cells.
Interestingly, it may also activate glial cells proliferation and differentiation, in the central
or in the peripheral nervous system. Focusing on the neural architecture and neurogenesis
in the nigrostriatal tract, Wang proposed Allo as a neurotrophic agent able to stimulate
the number of total cells and to re-establish the dopaminergic neurons circuitry (Wang,
2014). This striking approach has been so far suggested to cure neurodegenerative diseases,
such as Parkinson and/or Alzheimer. Indeed, Allo reduces β-amyloid protein levels and
neuroinflammation, revealing as efficient molecule for the treatment of Alzheimer and other
neurologic disorders. Brinton and colleagues presented a safe treatment with Allo that has
been optimized for neuroregeneration and reduction of Alzheimer symptoms. Moreover, by
tailoring doses/regimen to the different etiologies, Brinton proposes Allo as novel reliable
approach for multiple sclerosis, Niemann-Pick, diabetic neuropathy and traumatic brain injury
(Irwin et al., 2014). The brain of patients with multiple sclerosis presents a dysregulation
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in Allo biosynthesis. The hypothesis discussed by Power and
colleagues raised the possibility that changes in Allo biosynthe-
sis may control leukocyte functions and the neuroinflammation
associated to multiple sclerosis. They found that Allo administra-
tion ameliorates neurobehavioral deficits of animals with autoim-
mune demyelination, proposing its use for neuroinflammatory
pathologies (Noorbakhsh et al., 2014).
The pineal gland is still a neglected structure among neuroen-
docrinologists. Tsutsui and Haraguchi provided clear evidences
that the gland is an important neurosteroidogenic organ. They
reported a new neuroprotective role of Allo in the brain. Dur-
ing the development, Allo from the pineal gland prevents Purk-
inje cells death by suppressing the caspase-3 activity (Tsutsui and
Haraguchi, 2014).
Neurosteroids are promising drugs also for the treatment
of pain. However, they display some side effects such as seda-
tion, amnesia and tolerance, restricting their therapeutic use.
Poisbeau, Schumacher and colleagues overviewed the analgesic
effects of endogenous neurosteroids, focusing on pharmaco-
logic strategies aimed at stimulating local production of 3-alpha
reduced neurosteroids (Poisbeau et al., 2014). This approach
limits the side effects, targeting specific structures equipped
with the neurosteroid biosynthetic machinery, including the
mitochondrial translocation protein complex TSPO. In the
perspective of Puia and Magnaghi the functional cross-talk
between Allo, the protein kinase type C (PKC) and GABA-
AR was discussed. It was reviewed how GABA-AR is modu-
lated by Allo and/or PKC phosphorylation, through molecular
mechanisms that can be mutually interconnected (Puia et al.,
2015).
To further complicate the Allo’s action, the possibility to fig-
ure out alternative molecular mechanisms is becoming increas-
ingly credible. A family of newmembrane progesterone receptors
(mPRs) has been identified as putative target for this neuros-
teroid. Frye et al. (2014) faced Allo’s effects on behavioral pro-
cesses, involving rapid modulatory actions via GABA-AR and/or
n-methyl-D-aspartate (NMDA) receptors. They also characterize
the role of promiscuous nuclear receptor, the pregnane xenobi-
otic receptor (PXR), which may bind Allo in the central nervous
system. This mechanism is supposed to support Allo’s effects on
the midbrain ventral tegmental area (VTA), controlling lordosis
and sexual behavior.
In conclusion, Allo is a novel, promising, alternative and reli-
able drug with several neuroprotective properties. We very much
hope this issue will help readers to understand pros and cons of
Allo “neuroactions!”
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